Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • illinu
    Member
    • Jul 2013
    • 55

    #1

    Meracoulous assembler: has someone used it?

    Hi everyone,
    At the Assemblathon II competition there was an assembler reported as one which ranked higher about 10 times. It's called Meraculous but the authors failed to provide their program instructions to the Assemblathon paper (others did which helps getting the assembler working for the first time).

    In reading the Manual from Meraculous they say:
    We expect the user to convert data as needed into the following format, where line matches the following perl regex:
    \d+:\d+:\d+:\d+:\d+\/[12]:\S+:\S+

    I guess they refer to the header of each read in the fastq file?

    I don't understand why they need to make it so complicated and there seem to be no support page or google group.

    Has someone used this tool? Can someone give me a quick hint to modify the header of my reads:
    @HWI-M00991:47:000000000-A5JA9:1:1101:10000:10212 1:N:0:CTTGTA

    Thank you in advance
  • Brian Bushnell
    Super Moderator
    • Jan 2014
    • 2709

    #2
    I know the authors of Meraculous, so I'll notify them.

    Comment

    • GeneGolts
      Junior Member
      • Oct 2013
      • 5

      #3
      Hi, we're currently working on releasing a much updated version of Meraculous. What the Assemblathon-II paper refers to is way too old to support at this point, and the new version deals with the read headers a lot more robustly. You won't need to modify the header in your example. The software hasn't been made available to the general public yet, so please contact me directly and we'll discuss how to best get it out to you.

      Best,

      Eugene Goltsman
      [email protected]

      Comment

      • illinu
        Member
        • Jul 2013
        • 55

        #4
        Originally posted by GeneGolts View Post
        Hi, we're currently working on releasing a much updated version of Meraculous. What the Assemblathon-II paper refers to is way too old to support at this point, and the new version deals with the read headers a lot more robustly. You won't need to modify the header in your example. The software hasn't been made available to the general public yet, so please contact me directly and we'll discuss how to best get it out to you.

        Best,

        Eugene Goltsman
        [email protected]
        Eugene Goltsman,
        That's very kind of you.

        Thanks

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM
        • SEQadmin2
          Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
          by SEQadmin2



          Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
          ...
          07-09-2026, 11:10 AM
        • SEQadmin2
          Cancer Drug Resistance: The Lingering Barrier to Rising Survival
          by SEQadmin2



          Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

          There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
          07-08-2026, 05:17 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        10 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-23-2026, 11:41 AM
        0 responses
        11 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-20-2026, 11:10 AM
        0 responses
        23 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-13-2026, 10:26 AM
        0 responses
        37 views
        0 reactions
        Last Post SEQadmin2  
        Working...